Navigation Links
Does the Crowded TNF Market Really Need Two New Agents? Rheumatologists Provide Insight in the Wave One Report of LaunchTrends(TM): SIMPONI and CIMZIA
Date:7/31/2009

EXTON, Pa., July 31 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the wave one LaunchTrends(TM): SIMPONI and CIMZIA report. The survey was completed by U.S. Rheumatologists in late June 2009.

While awareness of both new TNF antagonists is relatively high, there are some troubling signs regarding initial impressions of these agents. The initial favorability rating for Simponi, for example, has slipped from 65% in the baseline report to 41% with the current wave of research. The initial favorability rating for Cimzia was significantly lower than both the baseline and current results for Simponi.

More than one-half of surveyed physicians have prescribed Simponi while less than one-third report trial of Cimzia. Over 80% of Simponi patients were switched from other biologics (primarily Humira) while a higher percent of the Cimzia patients were biologic naive. The majority of Rheumatologists see both of these agents as second or third line biologic options for the treatment of RA.

Dosing with Cimzia appears to be both a blessing and a curse -- once monthly administration has high patient appeal, but the loading dose, large volume, two injection requirement, and potential patient confusion are also noted as product disadvantages. Simponi is viewed as being significantly easier to administer. The Rheumatologists surveyed, however, view the products as extremely similar. While both Simponi and Cimzia are expected to gain market share in the next six months, the combined share of the two agents is not expected to exceed 15% of the biologic share in Rheumatoid Arthritis.

Looking to the future, Rheumatologists report high familiarity with Roche's ACTEMRA, an IL-6 blocker in Phase III clinical trials. Unlike the established TNFs (Enbrel, Humira, and Remicade) which have been the target of Cimzia and Simponi's launches, the survey respondents anticipate that Actemra would be most likely to replace BMS's Orencia in their practices.

LaunchTrends(TM) measure launch effectiveness of new products from FDA approval through six months post launch. The next wave of this report, measuring uptake at three months post launch, will be fielded on August 17. The results will be published in mid-September.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To purchase this report or to learn more about BioTrends syndicated publications, please contact Paul Callahan at (610) 363-3872 or visit us at www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Crowded emergency departments pose greater risks for patients with heart attacks
2. Crowded Households Raise Womens Heart Risk
3. Osteotech to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
4. Living Green Marketplace Announces the Cancer Care Wellness Box to Bring Comfort to Cancer Patients During Medical Treatment
5. Air Methods to Report Second Quarter Financial Results After Market Close on Thursday, August 6, 2009
6. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
7. Frost & Sullivan Awards Agfa Healthcare for Brazilian Market Penetration Leadership in 2009
8. Health Market Science Unveils CompleteView, the Most Comprehensive Master Data Management (MDM) Solution Available in the Healthcare Market
9. NuVasive to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
10. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
11. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Thomas Jefferson ... Witness , was awarded a $300,000 grant from The Pew Center for Arts ... with ambiguity and the recognition of one’s own limits among health professions students. ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... $5,000 grant from the C. R. Bard Foundation, Inc. to support ... Hills , a service available through the nonprofit home care agency. Using evidence-based ...
(Date:7/21/2017)... ... 21, 2017 , ... In the first prospective ACL reconstruction ... Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain a ... over time. The study, presented today at the American Orthopaedic Society for ...
(Date:7/20/2017)... MA (PRWEB) , ... July 20, 2017 , ... ... form of blood and bone marrow cancer that progresses rapidly without treatment. Newly ... recommended to reduce the chance of reoccurrence and relapse. With such a ...
(Date:7/20/2017)... ATLANTA, Ga. (PRWEB) , ... July 20, 2017 , ... ... and equal access to medicine for everyone affected by diabetes, is teaming up with ... the five-day global event kicks off on July 24th. , “Team Type 1’s ...
Breaking Medicine News(10 mins):
(Date:7/19/2017)...  Mako Medical Laboratories partnered with Secretary Strickland, the ... Fund (MFA) to bring 140 soldiers back home to ... families one last time before being deployed. Mako Medical ... logistics needed for these soldiers. "Mako Medical Laboratories is ... We just wish we could bring them all home," ...
(Date:7/13/2017)...  Centurion Medical Products, a leader in medical product innovation and ... removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of a ... pain while preventing unneeded emergency department admission due to severe fecal ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
Breaking Medicine Technology: